Having trouble accessing articles? Reset your cache.

Riferminogen pecaplasmid: Phase III data

In the double-blind, international Phase III TAMARIS trial in 525 patients with CLI and skin lesions who were not eligible for

Read the full 212 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE